Kenvue to Showcase 22 New Sets of Clinical Data at AAD

Kenvue announced it will share 22 data sets detailing new Kenvue skin science research at the American Academy of Dermatology (AAD) Association annual meeting, March 8-12, in San Diego.

Evidence will be presented on the clinical effectiveness of Neutrogena and Aveeno formulations in moisturizing skin, improving skin barrier, protecting against UVA sun damage, and rapidly reducing facial acne. Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511.

“This is our first time presenting as Kenvue at the annual AAD meeting, allowing us a great opportunity to meet with leaders across dermatology and share our latest category-defining research that supports the value of our iconic brands as a part of everyday care,” Adam Ricciardone2, Head of R&D, Global Skin Health & Beauty and Head of R&D North America, said in a company news release. “This evidence illustrates our ongoing commitment to delivering science-backed, care-forward experiences that are loved by consumers and recommended by healthcare professionals and experts.”

In six new clinical studies being presented at AAD, Kenvue investigators found that oat-containing moisturizers developed by Aveeno and Neutrogena scientists made the skin’s microbiome more resilient in a variety of populations. These include young children predisposed to eczema, women with dry skin, adults with mild to moderate eczema, and adults receiving immunobiological treatment for psoriasis, according to Kenvue. 

Across these studies, findings showed that consumers enjoyed improved quality of life while using the moisturizing formulations. Specifically, product users experienced less itchiness, scaliness and self-consciousness about their appearance, or in the case of the infants, improvements to the skin’s microbiome associated with a decreased risk of eczema.

Additional data to be presented at AAD demonstrates the benefits of Kenvue’s formulations for skin hydration, sun protection and acne control.

Studies presented will include:

• Novel Natural Moisturizing Factor and Lipid-Containing Face Cream Induces Aquaporin-3 and Filaggrin Expression Associated with Barrier Improvements and Sustained Clinical Hydration in Extra-Dry Skin; Bernhardt KT, et al.
• Demonstrating the Clinical Effectiveness of Mineral Sunscreens in Protecting the Skin Against Ultraviolet A (UVA) Radiation-Induced Pigmentation; Shyr TC, et al.
• The Science Behind a Viral Trend: Demonstrating Tolerance and Efficacy of Hydrocolloid Patch for Facial Acne; Kosmoski G, et al.

On Friday and Saturday, Kenvue experts and key opinion leaders will also host R&D Theater presentations in the booth. See here for a full list of topics and times.